The splendour of tolerogenic cell therapies
The biotech company Idogen develops tolerogenic cell therapies to prevent biological drugs, transplanted organs or the body’s own cells or tissue from being attacked by the patient’s immune system.
Idogen was founded 2008 in Lund, but is today a public company listed on the Nasdaq First North Growth Market. The company has now entered into a very exciting phase where it’s first clinical trial,